Browse by phase
Featured Phase 3 & 4 trials recruiting now
Late-stage trials enrolling new participantsRecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
TG Therapeutics, Inc.
Ublituximab · Ublituximab
360Details
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
Ublituximab · Placebo
25 states800Details
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Amgen
Ocrelizumab (US) · Ocrelizumab (EU)
17 states444Details
Browse by state
Active MS trials across 48 statesAll MS trials
Showing 24 of 577 trials
ActivePhase 2
HB-adMSCs for the Treatment of Patients With Multiple Sclerosis
Hope Biosciences Research Foundation
Autologous HB-adMSCs
1 state10Details
ActiveNA
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
University of California, San Francisco
MS CATCH
1 state100Details
ActiveNA
A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.
St. Olavs Hospital
Digital Cognitive Behavioral Therapy … · Digital patient education about insom…
550Details
ActiveNA
A Health Action Process Approach Online Intervention for People With Multiple Sclerosis
University of Illinois at Urbana-Champaign
MSPA eClass
1 state60Details
ActivePhase 4
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Ofatumumab · Disease modifying treatment (DMT)
19 states136Details
Active
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
Celestra Health Systems
1 state90Details
Active
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Bristol-Myers Squibb
1 state9000Details
ActivePhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Hoffmann-La Roche
Ocrelizumab
26 states1300Details
Active
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Biogen
Natalizumab
1 state400Details
ActivePhase 1
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
Bruce Cree
KYV-101 (Biological) - 0.33 ×10^8 cells · KYV-101 (Biological) - 1 ×10^8 cells
1 state10Details
ActivePhase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Eli Lilly and Company
LY3541860 · Placebo
5 states63Details
ActivePhase 2
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
Zenas BioPharma (USA), LLC
Obexelimab · Placebo
11 states93Details
ActivePhase 2
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Hoffmann-La Roche
Ocrelizumab
5 states23Details
ActivePhase 4
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
Bristol-Myers Squibb
BMS-986374
84Details
Active
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Biogen
Diroximel Fumarate · Dimethyl Fumarate
1 state10500Details
ActivePhase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Hoffmann-La Roche
Ocrelizumab
13 states927Details
ActivePhase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Hoffmann-La Roche
Ocrelizumab · Ocrelizumab Placebo
11 states188Details
ActiveNA
A Study to Evaluate White Matter Hyperintensities in Migraine
Mayo Clinic
Brain Neuroimaging
1 state50Details
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985Details
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Fenebrutinib · Teriflunomide
23 states746Details
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Ocrelizumab · Placebo
5 states1013Details
ActivePhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
16 states769Details
ActivePhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
20 states864Details
Page 1 of 25
Check out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
